Kevin Chu joined F-Prime Capital as an Analyst in 2014. Prior to F-Prime Capital, Kevin was an Associate Consultant with IMS Consulting Group in New York, where he advised biopharmaceutical clients on development and commercial strategy across multiple therapeutic areas. Kevin currently works closely with the Fidelity Growth Partners Asia team to manage portfolio companies and new investment opportunities in China.
Kevin received his B.S.E. in Biomedical Engineering from the University of Pennsylvania.